Synairgen PLC - respiratory drug discovery company based in Southampton - Commences dosing in the inhaled interferon beta formulation - SNG001 - sub-study of the US government-funded ACTIV-2 phase II/III trial, evaluating patients with mild to moderate Covid-19 symptoms who do not yet require hospitalisation.
Antiviral therapy SNG001 is a proposed treatment for people suffering from chronic obstructive pulmonary disease. The company previously said that two phase II clinical trials in asthma showed that the inhaled SNG001 treatment activated antiviral pathways in the lung and improved lung function in patients with a respiratory viral infection.
Synairgen notes if an investigational agent demonstrates safety and reduces symptoms through 28 days following dosing, the ACTIV-2 trial will expand from a phase II to a phase III study to gather additional data from a larger pool of volunteers.
"We are delighted that our inhaled interferon beta formulation has been entered into this US government-funded phase II/III study and that dosing has now commenced. With mutations of Covid-19 now emerging, and the concern that mutations may render the vaccines less effective, the need for broad spectrum treatment options remains very high. We look forward to tracking the progress of the ACTIV-2 trial alongside our other Covid-19 trials," says Chief Executive Richard Marsden.
Current stock price: 191.48 pence
Year-to-date change: up 25%
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Synairgen (SNG)